Coloplast A/ S stock (DK0060448595): H1 2025/ 26 results show 6% growth amid impairment

Coloplast A/S, the Danish medical device maker, published its interim financial report for H1 2025/26 (October 2025 to March 2026) on May 12, 2026, via GlobeNewswire. The company posted 6% organic growth in Q2 and overall H1, driven by core segments like ostomy and continence care, but recorded a DKK 3 billion goodwill impairment on its Kerecis unit. FY 2025/26 organic growth guidance was narrowed to 5-6%, according to GlobeNewswire as of 05/12/2026 and Investing.com as of 05/12/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Coloplast A/S: core business model

Coloplast A/S develops and markets medical devices and services focused on intimate healthcare needs, addressing chronic conditions such as ostomy, continence, interventional urology, voice and respiratory care, and wound and tissue repair. The company operates globally with a strong emphasis on innovation in chronic care solutions.

For fiscal 2025/26 first nine months (ended December 31, 2025), reported February 4, 2026, Coloplast A/S achieved 6% organic revenue growth, with US sales up 7%, per Coloplast IR as of 02/04/2026. EBIT margin reached 28%, supported by pricing and efficiency.

Main revenue and product drivers for Coloplast A/S

Ostomy care and continence care represent the largest revenue contributors for Coloplast A/S, benefiting from steady demand in aging populations. Interventional urology and wound care segments also drive growth, particularly in the US where reimbursement dynamics favor established players.

In H1 2025/26, Q2 organic growth was 6% with EBIT growth of 6%, though offset by the Kerecis impairment and currency effects, leading to an EBIT margin of 26%, according to the interim report published May 12, 2026, via GlobeNewswire as of 05/12/2026.

Industry trends and competitive position

The medical devices sector, especially chronic care, sees robust demand driven by demographics and rising chronic disease prevalence. Coloplast A/S holds a leading position in ostomy and continence, with significant US exposure making it relevant for American investors tracking global healthcare leaders.

Why Coloplast A/S matters for US investors

Coloplast A/S derives substantial revenue from the US, its largest single market, where it competes in high-margin chronic care niches. US investors gain exposure to Europe's medtech stability alongside North American growth opportunities amid healthcare spending trends.

Conclusion

Coloplast A/S's H1 2025/26 results highlight resilient organic growth in core chronic care segments despite the Kerecis impairment and guidance adjustment. Strong US performance underscores its strategic importance, while margin pressures from currencies and one-offs warrant monitoring. The company remains focused on innovation and efficiency in a growing medtech landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.